HALO vs. SMMT: Halozyme Therapeutics vs. Summit Therapeutics Stock Comparison
How do Halozyme Therapeutics (HALO) and Summit Therapeutics (SMMT) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Halozyme Therapeutics (HALO) and Summit Therapeutics (SMMT) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
| Profile Item | HALO | SMMT |
|---|---|---|
| Name | Halozyme Therapeutics Inc. | Summit Therapeutics Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 11.81 billion USD | 13.06 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | March 16, 2004 | March 5, 2015 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | HALO | SMMT |
|---|---|---|
| Total Return (1Y) | 50.94% | -2.48% |
| Total Return (3Y, Annualized) | 41.08% | 116.18% |
| Total Return (5Y, Annualized) | 21.68% | 26.89% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
Summit Therapeutics (SMMT) reports a negative beta of -1.51, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Halozyme Therapeutics (HALO) has a non-negative beta of 0.96.
| Metric | HALO | SMMT |
|---|---|---|
| Volatility (1Y, Annualized) | 41.19% | 75.06% |
| Beta (5Y) | 0.96 | -1.51 |
| Max Drawdown (5Y) | -49.06% | -87.64% |
| Avg. Volume (3M) | 2.29M | 6.19M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | HALO | SMMT |
|---|---|---|
| Sharpe Ratio (1Y) | 1.13 | -0.09 |
| Sortino Ratio (1Y) | 1.78 | -0.13 |
Profitability
ROE (TTM)
Summit Therapeutics (SMMT) reports a negative ROE of -220.01%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Halozyme Therapeutics (HALO) reports 216.38%, ranking against industry peers normally.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
216.38%
- HALO
- 216.38%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
-220.01%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- SMMT
- -220.01%
Net Margin (TTM)
Halozyme Therapeutics (HALO) at 26.93% converts revenue to bottom-line profit above its industry’s benchmark range, while Summit Therapeutics (SMMT) at 0.00% keeps roughly the typical share for its industry.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.93%
- HALO
- 26.93%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- Max
- 18.05%
- Q3
- 4.78%
- SMMT
- 0.00%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Halozyme Therapeutics (HALO) at 59.84% operates in the top operating margin quartile, ahead of Summit Therapeutics (SMMT) at 0.00%, which runs around its industry’s norm.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
59.84%
- Max
- 83.12%
- HALO
- 59.84%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- Max
- 83.12%
- Q3
- 14.77%
- SMMT
- 0.00%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | HALO | SMMT |
|---|---|---|
| ROE (TTM) | 216.38% | -220.01% |
| ROA (TTM) | 22.42% | -111.99% |
| Net Margin (TTM) | 26.93% | 0.00% |
| Operating Margin (TTM) | 59.84% | 0.00% |
| Gross Margin (TTM) | 77.74% | 0.00% |
Growth
Revenue Growth
Only one side can be read here: Halozyme Therapeutics (HALO) reports revenue growth of 37.55%, ranked against its industry; Summit Therapeutics (SMMT) has no revenue growth figure this period.
EPS Growth
Only one side can be read here: Halozyme Therapeutics (HALO) reports EPS growth of -25.36%, ranked against its industry; Summit Therapeutics (SMMT) has no EPS growth figure this period.
Growth Metrics
| Metric | HALO | SMMT |
|---|---|---|
| Revenue Growth (YoY) | 37.55% | -- |
| Revenue Growth (3Y CAGR) | 28.38% | -- |
| EPS Growth (YoY) | -25.36% | -- |
| EPS Growth (3Y CAGR) | 21.14% | -- |
Financial Strength
Current Ratio (MRQ)
Both Halozyme Therapeutics (HALO) at 3.88 and Summit Therapeutics (SMMT) at 5.99 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.88
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- HALO
- 3.88
- Q1
- 2.47
- Min
- 0.10
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.99
- Max
- 25.13
- Q3
- 12.13
- SMMT
- 5.99
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Only one side’s leverage can be read here: Summit Therapeutics (SMMT) carries debt-to-equity ratio of 0.04 against its industry range, while Halozyme Therapeutics (HALO) reports no figure this period.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
- HALO
- --
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.04
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- SMMT
- 0.04
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | HALO | SMMT |
|---|---|---|
| Current Ratio (MRQ) | 3.88 | 5.99 |
| Debt / Equity (MRQ) | -- | 0.04 |
| Net Debt / EBITDA | 1.90 | -- |
Dividends
Dividend Yield (TTM)
Neither Halozyme Therapeutics (HALO) nor Summit Therapeutics (SMMT) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- HALO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- SMMT
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Halozyme Therapeutics (HALO) nor Summit Therapeutics (SMMT) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- HALO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- SMMT
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | HALO | SMMT |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Halozyme Therapeutics (HALO) trades at 25.91 times trailing earnings, ranked against its peers, while Summit Therapeutics (SMMT) has no P/E ratio this period.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
25.91
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- HALO
- 25.91
- Q1
- 13.30
- Min
- 0.07
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- SMMT
- --
P/S Ratio (TTM)
A sales-based read is only available for Halozyme Therapeutics (HALO), whose P/S ratio of 6.55 ranks against industry peers; Summit Therapeutics (SMMT) reports no figure this period.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.55
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- HALO
- 6.55
- Q1
- 3.01
- Min
- 0.01
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
- SMMT
- --
P/B Ratio (MRQ)
Halozyme Therapeutics (HALO) reports a negative P/B ratio of -213.67, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Summit Therapeutics (SMMT) reports 23.13, ranking against industry peers normally.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
-213.67
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
- HALO
- -213.67
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.13
- SMMT
- 23.13
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | HALO | SMMT |
|---|---|---|
| P/E Ratio (TTM) | 25.91 | -- |
| P/S Ratio (TTM) | 6.55 | -- |
| P/B Ratio (MRQ) | -213.67 | 23.13 |
| Free Cash Flow Yield (TTM) | 3.48% | -1.64% |